UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
URGN 10.30.2024
Date of Upcoming Event:2024-11-06
Name of Upcoming Event:Earnings Call
About Gravity Analytica
Recent News
- 01.22.2025 - New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
- 01.15.2025 - ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
- 12.06.2024 - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Recent Filings
Conference Call and Webcast Scheduled for
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relationswebsite. Following the live webcast, a replay will be available on the site for approximately 30 days.
About
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241030832940/en/
INVESTORS:
MEDIA:
Source: